Literature DB >> 10535454

Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance.

C Weyer1, C Bogardus, R E Pratley.   

Abstract

With the release of the new 1997 American Diabetes Association diagnostic criteria, a new category was introduced, termed "impaired fasting glucose" (IFG). The metabolic abnormalities of individuals with IFG, compared with those with impaired glucose tolerance (IGT) (World Health Organization criteria), remain to be elucidated. We assessed insulin action (hyperinsulinemic clamp), insulin secretion (25-g intravenous glucose tolerance test), and endogenous glucose output (EGO) (3-(3)H-glucose) in 434 nondiabetic Pima Indians with either normal (NFG; <6.1 mmol/l) or impaired (IFG; 6.1-7.0 mmol/l) fasting glucose and with either normal (NGT; 2-h glucose <7.8 mmol/l) or impaired (IGT; 2-h glucose 7.8-11.1 mmol/l) glucose tolerance: NFG/NGT (n = 307), IFG/NGT (n = 11), NFG/IGT (n = 98), and IFG/IGT (n = 18). Compared with the NFG/NGT group, individuals with IFG/NGT had lower maximal insulin-stimulated glucose disposal (M; -20%, P < 0.01), a lower acute insulin response (AIR) to intravenous glucose (-33%, P < 0.05), and higher EGO (8%, P = 0.055). Individuals with NFG/IGT also had lower M (-21%, P < 0.001) and lower AIR (-8%, P < 0.05), but normal EGO (-1%, NS). Individuals with IFG/IGT showed the most severe abnormalities in M (-27%), AIR (-51%), and EGO (+13%) (all P < 0.001 compared with NFG/NGT). These group differences could be explained by the observation that AIR and EGO, but not M, were more strongly related to the fasting than to the 2-h glucose concentration. Thus, Pima Indians with isolated IFG and isolated IGT show similar impairments in insulin action, but those with isolated IFG have a more pronounced defect in early insulin secretion and, in addition, increased EGO. More severe metabolic abnormalities are present in Pima Indians with combined IFG and IGT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10535454     DOI: 10.2337/diabetes.48.11.2197

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  82 in total

1.  The Gly1057Asp polymorphism in IRS-2 interacts with obesity to affect beta cell function.

Authors:  N Stefan; A Fritsche; F Machicao; O Tschritter; H U Häring; M Stumvoll; M Stumvogel
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

2.  A novel surrogate index for hepatic insulin resistance.

Authors:  J Vangipurapu; A Stančáková; T Kuulasmaa; J Paananen; J Kuusisto; E Ferrannini; M Laakso
Journal:  Diabetologia       Date:  2010-11-25       Impact factor: 10.122

Review 3.  Diabetes prevention: can insulin secretagogues do the job?

Authors:  Barbara Westerhaus; Aidar R Gosmanov; Guillermo E Umpierrez
Journal:  Prim Care Diabetes       Date:  2010-12-24       Impact factor: 2.459

4.  To: Godsland IF, Jeffs JA, Johnston DG (2004) loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47:1157-1166.

Authors:  M A Abdul-Ghani; R A DeFronzo
Journal:  Diabetologia       Date:  2005-08-17       Impact factor: 10.122

5.  Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes?

Authors:  Leigh Perreault; Bryan C Bergman; Mary C Playdon; Chiara Dalla Man; Claudio Cobelli; Robert H Eckel
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-03       Impact factor: 4.310

6.  Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose.

Authors:  Muhammad Abdul-Ghani; Hussein Al Jobori; Giuseppe Daniele; John Adams; Eugenio Cersosimo; Curtis Triplitt; Ralph A DeFronzo
Journal:  Diabetes       Date:  2017-06-13       Impact factor: 9.461

Review 7.  Impaired fasting glucose as a treatment target in diabetes management.

Authors:  Rene A Oliveros; Adrienne S Zion; Yelena Rosenberg; Carrie Lynn Selvaraj; Robert Chilton
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

Review 8.  Exercise resistance across the prediabetes phenotypes: Impact on insulin sensitivity and substrate metabolism.

Authors:  Steven K Malin; Zhenqi Liu; Eugene J Barrett; Arthur Weltman
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

Review 9.  Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion.

Authors:  Richard E Pratley; Christian Weyer
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

10.  Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

Authors:  R A DeFronzo; M A Banerji; G A Bray; T A Buchanan; S Clement; R R Henry; A E Kitabchi; S Mudaliar; N Musi; R Ratner; P Reaven; D C Schwenke; F D Stentz; D Tripathy
Journal:  Diabetologia       Date:  2009-12-10       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.